Details

Autor(en) / Beteiligte

• Niesvizky, Ruben
• Jayabalan, David S.
• Christos, Paul J.
• Furst, Jessica R.
• Naib, Tara
• Ely, Scott
• Jalbrzikowski, Jessica
• Pearse, Roger N.
• Zafar, Faiza
• Pekle, Karen
• LaRow, April
• Lent, Richard
• Mark, Tomer
• Cho, Hearn J.
• Shore, Tsiporah
• Tepler, Jeffrey
• Harpel, John
• Schuster, Michael W.
• Mathew, Susan
• Leonard, John P.
• Mazumdar, Madhu
• Chen-Kiang, Selina
• Coleman, Morton

Titel

BiRD (Biaxin [clarithromycin]/Revlimid [lenalidomide]/dexamethasone) combination therapy results in high complete- and overall-response rates in treatment-naive symptomatic multiple myeloma

Ist Teil von

• Blood, 2008-02, Vol.111 (3), p.1101-1109

Ort / Verlag

Washington, DC: Elsevier Inc

Erscheinungsjahr

2008

Link zum Volltext

Quelle

Alma/SFX Local Collection

Beschreibungen/Notizen

• This trial determined the safety and efficacy of the combination regimen clarithromycin (Biaxin), lenalidomide (Revlimid), and dexamethasone (BiRD) as first-line therapy for multiple myeloma. Patients received BiRD in 28-day cycles. Dexamethasone (40 mg) was given orally once weekly, clarithromycin (500 mg) was given orally twice daily, and lenalidomide (25 mg) was given orally daily on days 1 to 21. Objective response was defined by standard criteria (ie, decrease in serum monoclonal protein [M-protein] by at least 50%, and a decrease in urine M-protein by at least 90%). Of the 72 patients enrolled, 65 had an objective response (90.3%). A combined stringent and conventional complete response rate of 38.9% was achieved, and 73.6% of the patients achieved at least a 90% decrease in M-protein levels. This regimen did not interfere with hematopoietic stem-cell harvest. Fifty-two patients who did not go on to receive transplants received continued therapy (complete response, 37%; very good partial response, 33%). The major adverse events were thromboembolic events, corticosteroid-related morbidity, and cytopenias. BiRD is an effective regimen with manageable side effects in the treatment of symptomatic, newly diagnosed multiple myeloma. This trial was registered at www.clinicaltrials.gov as #NCT00151203.